Patient preferences and health state utilities associated with dulaglutide and semaglutide injection devices among patients with type 2 diabetes in Italy

AbstractAims: Several glucagon like peptide-1(GLP-1) receptor agonists are available as weekly injections for treatment of type 2 diabetes. These medications vary in their injection devices, and these differences could impact quality of life and patient preference. The purpose of this study was to examine patient preferences and estimate health state utilities associated with injection devices for two weekly GLP-1 therapies.Materials and methods: Participants with type 2 diabetes in Italy (Milan, Rome) valued three health state vignettes in time trade-offinterviews. The health states had identical descriptions of type 2 diabetes, but differed in description of the treatment process: (1) oral treatment regimen, (2) oral plus weekly dulaglutideinjection, (3) oral plus weekly semaglutideinjection.Results: A total of 216 participants completed interviews (57.9% male; mean age =60.5). Almost all patients (99.5%) preferred the oral health state over either injection health state. Comparing between the two i...